5 Key Takeaways

• 1

  Life Biosciences is evaluating ER-100, an epigenetic restoration therapy, in a clinical trial for optic neuropathies, including glaucoma and NAION.

• 2

  The reported findings are from the first 3 participants in the glaucoma cohort, who received the lowest ER-100 dose.

• 3

  ER-100 was well tolerated in these 3 participants, with no adverse events or dose-limiting toxicities reported.

• 4

  Humphrey visual field testing showed evidence of improvement across multiple visual field points.

• 5

  The findings are preliminary and represent the first clinical data reported for ER-100.